Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT101 in Healthy Volunteers
NCT04589403Phase 1Completed
- Sponsor
- Op-T
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Placebo with OPT101 (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 21 days, Rate and type of adverse events at 48 hours and 3 more. Started Feb 2021; status: completed.
02
Drugs
OPT101
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04589403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589403.